These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 17335684)

  • 21. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
    Palumbo A; Mateos MV; Bringhen S; San Miguel JF
    Blood Rev; 2011 Jul; 25(4):181-91. PubMed ID: 21497966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide efficacy in bortezomib-resistant myeloma.
    Gozzetti A; Crupi R; Defina M; Bocchia M
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
    [No Abstract]   [Full Text] [Related]  

  • 23. [New drugs for myeloma].
    Moreau P
    Presse Med; 2006 Sep; 35(9 Pt 2):1303-8. PubMed ID: 16969325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The treatment of relapsed and refractory multiple myeloma.
    Richardson P; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Chauhan D; Munshi N; Anderson K
    Hematology Am Soc Hematol Educ Program; 2007; ():317-23. PubMed ID: 18024646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Latest advances and current challenges in the treatment of multiple myeloma.
    Mahindra A; Laubach J; Raje N; Munshi N; Richardson PG; Anderson K
    Nat Rev Clin Oncol; 2012 Feb; 9(3):135-43. PubMed ID: 22349016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current multiple myeloma treatment strategies with novel agents: a European perspective.
    Ludwig H; Beksac M; Bladé J; Boccadoro M; Cavenagh J; Cavo M; Dimopoulos M; Drach J; Einsele H; Facon T; Goldschmidt H; Harousseau JL; Hess U; Ketterer N; Kropff M; Mendeleeva L; Morgan G; Palumbo A; Plesner T; San Miguel J; Shpilberg O; Sondergeld P; Sonneveld P; Zweegman S
    Oncologist; 2010; 15(1):6-25. PubMed ID: 20086168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenalidomide for bortezomib-resistant multiple myeloma.
    Briani C; Berno T; Campagnolo M; Zambello R
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
    [No Abstract]   [Full Text] [Related]  

  • 29. [Molecular targeting therapy for multiple myeloma].
    Takatoku M
    Nihon Rinsho; 2007 Dec; 65(12):2345-50. PubMed ID: 18069281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic strategies for the treatment of multiple myeloma.
    Saini N; Mahindra A
    Discov Med; 2013 Apr; 15(83):251-8. PubMed ID: 23636142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of myeloma in patients not eligible for transplantation.
    Jagannath S
    Curr Treat Options Oncol; 2005 May; 6(3):241-53. PubMed ID: 15869735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance treatment in multiple myeloma.
    Harousseau JL
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
    [No Abstract]   [Full Text] [Related]  

  • 33. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
    Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV;
    Blood; 2009 Aug; 114(9):1729-35. PubMed ID: 19561323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Chauhan D; Tian Z; Nicholson B; Kumar KG; Zhou B; Carrasco R; McDermott JL; Leach CA; Fulcinniti M; Kodrasov MP; Weinstock J; Kingsbury WD; Hideshima T; Shah PK; Minvielle S; Altun M; Kessler BM; Orlowski R; Richardson P; Munshi N; Anderson KC
    Cancer Cell; 2012 Sep; 22(3):345-58. PubMed ID: 22975377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
    Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
    J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
    Cavo M
    Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple myeloma.
    Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
    Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.